GLP-1 Research

Ozempic is FDA-approved for type 2 diabetes, but clinical trials in non-diabetic adults show significant fat loss benefits…

The landmark FLOW trial showed semaglutide reduced hard kidney disease endpoints by 24% — here's what the full…

The science on artificial sweeteners and GLP-1 is more complicated than 'zero calories, zero consequences' — here's what…

Semaglutide is a GLP-1 receptor agonist FDA-approved for weight loss that helped clinical trial participants lose nearly 15%…

A 2025 meta-analysis of 85,373 participants confirms GLP-1 receptor agonists significantly reduce major cardiovascular events and kidney failure…

Semaglutide has a roughly seven-day half-life and clears your system in about five weeks after your last dose…

Lipoprotein(a) is a genetically driven cardiovascular risk factor that standard cholesterol treatments rarely address — and GLP-1 receptor…

The FDA has approved an oral semaglutide pill for obesity — here's what the science actually shows and…

GLP-1 medications drive impressive weight loss, but research shows a real risk of muscle loss — here's what…

Semaglutide helps with weight management by mimicking GLP-1 to suppress appetite, reduce food noise, slow gastric emptying, and…